ArticleJournal of molecular histology2025
piR-38,736 promotes gastric cancer cell proliferation by downregulating SMAD4 expression.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
PIWI-interacting RNAs (piRNAs) play an important role in cancer development and progression. Although recent studies had advanced our understanding of the functions of various piRNAs in cancer, the specific role of piR-38736 in gastric cancer remained poorly understood. This study aimed to investigate the clinical significance and underlying mechanisms of piR-38736 in gastric cancer. This study found that piR-38736 was significantly upregulated in gastric cancer cells and tissues. Positive piR-38736 expression was closely correlated with larger tumor size and medium to poor differentiation. Survival analysis revealed that patients with positive piR-38736 expression had significantly shorter survival times compared to those with negative expression. Knockdown of piR-38736 markedly inhibited cell proliferation and tumor growth in gastric cancer. Furthermore, piR-38736 was found to directly bind to the 3' untranslated region (UTR) of SMAD4 mRNA, resulting in significant downregulation of SMAD4 at both the mRNA and protein levels upon overexpression of piR-38,736. In conclusion, these findings indicate that piR-38,736 promotes cell proliferation and tumor growth in gastric cancer by downregulating SMAD4 expression. piR-38,736 may serve as a prognostic biomarker and a potential therapeutic target for gastric cancer. Further studies are required to fully elucidate the underlying mechanisms of piR-38,736 and explore its clinical implications in gastric cancer management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.